Genomic Amplification of TBC1D31 Promotes Hepatocellular Carcinoma Through Reducing the Rab22A‐Mediated Endolysosomal Trafficking and Degradation of EGFR
Advanced Science · 2024
DOI: 10.1002/advs.202405459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Pengbo Cao und 21 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medical Proteomics, National Center for Protein Sciences at Beijing, Beijing Institute of Radiation Medicine, Beijing, 100850…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, ErbB Receptors, GTPase-Activating Proteins, Liver Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Major Research Plan of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinomas (HCCs) are characterized by a vast spectrum of somatic copy number alterations (CNAs); however, their functional relevance is largely unknown. By performing a genome‐wide survey on prognosis‐associated focal CNAs in 814 HCC patients by an integrative computational framework based on transcriptomic data, genomic amplification is identified at 8q24.13 as a promising candidate. Further evidence is provided that the 8q24.13 amplification‐driven overexpression of Rab GTPase activating protein TBC1D31 exacerbates HCC growth and metastasis both in vitro and in vivo through activating Epidermal growth factor receptor (EGFR) signaling. Mechanistically, TBC1D31 acts as a Rab GTPase activating protein to catalyze GTP hydrolysis for Rab22A and then reduces the Rab22A‐mediated endolysosomal trafficking and degradation of EGFR. Notably, overexpression of TBC1D31 markedly increases the resistance of HCC cells to lenvatinib, whereas inhibition of the TBC1D31‐EGFR axis can reverse this resistance phenotype. This study highlights that TBC1D31 at 8q24.13 is a new critical oncogene, uncovers a novel mechanism of EGFR activation in HCC, and proposes the potential strategies for treating HCC patients with TBC1D31 amplification or overexpression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medical Proteomics, National Center for Protein Sciences at Beijing, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
- School of Life Sciences, Tsinghua University, Beijing, 100084, China.
- University of South China, Hengyang, 421001, China.
- Guangxi Medical University, Nanning, 530021, China.
- State Key Laboratory of Medical Proteomics, National Center for Protein Sciences at Beijing, Beijing Institute of Lifeomics, Beijing, 102206, China.
- Hebei University, Baoding, 071000, China.
ORCID-Profile: Pengbo Cao, Gangqiao Zhou
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Major Research Plan of the National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Cao, P., Chen, H., Zhang, Y., Zhang, Q., Shi, M., Han, H., Wang, X., Jin, L., Guo, B., Hao, R., Zhao, X., Li, Y., Gao, C., Liu, X., Wang, Y., Yang, A., Yang, C., Si, A., Li, H., …, & Zhou, G. (2024). Genomic Amplification of TBC1D31 Promotes Hepatocellular Carcinoma Through Reducing the Rab22A‐Mediated Endolysosomal Trafficking and Degradation of EGFR. Advanced Science. https://doi.org/10.1002/advs.202405459
Vancouver
Cao P, Chen H, Zhang Y, Zhang Q, Shi M, Han H, et al. Genomic Amplification of TBC1D31 Promotes Hepatocellular Carcinoma Through Reducing the Rab22A‐Mediated Endolysosomal Trafficking and Degradation of EGFR. Advanced Science. 2024. doi:10.1002/advs.202405459
BibTeX
@article{Cao2024,
author = {Cao, Pengbo and Chen, Hongxia and Zhang, Ying and Zhang, Qi and Shi, Mengting and Han, Huihui and Wang, Xiaowen and Jin, Liang and Guo, Bingqian and Hao, Rongjiao and Zhao, Xi and Li, Yuanfeng and Gao, Chengming and Liu, Xinyi and Wang, Yahui and Yang, Aiqing and Yang, Chenning and Si, Anfeng and Li, Hua and Song, Qingfeng and He, Fuchu and Zhou, Gangqiao},
title = {Genomic Amplification of TBC1D31 Promotes Hepatocellular Carcinoma Through Reducing the Rab22A‐Mediated Endolysosomal Trafficking and Degradation of EGFR},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202405459}
}
EUVIMED